Alexander Ja-Ho Chou, MD

Professor of Clinical Pediatrics

Hematology and Oncology (Pediatrics)

Contact & profiles

Appointments

Professor of Clinical PediatricsPrimary
Pediatrics · 2023–
Physician
NewYork-Presbyterian Hospital

Past Appointments

Assistant Professor of Pediatrics
Pediatrics · 2021–2023
Assistant Professor of Pediatrics
Pediatrics · 2012–2017
Fellow in Pediatrics
Pediatrics · 2002–2005

Show all 5

Instructor in Pediatrics
Pediatrics · 2001–2002
Clinical Associate in Pediatrics
Pediatrics · 1999–2001

Centers

Clinical & Translational Science Center
Sandra and Edward Meyer Cancer Centerresearch
Cancer Therapeutics

Education

M.D., Medicine
Weill Cornell Medical College, Cornell University, 1998
B.A., Biology
University of Pennsylvania, 1994

Publications

Funding

Active

4 grants

MPI
COG NCTN Network Group Operations Center
National Cancer Institute · 2021–2032 · via Children's Oncology Group· 2 renewals
U10CA180886-12
Sub-PI
WWWW Foundation, Inc: COGFndn_NY018_2026_QuadW_CSBAO_Tissue Incentives
WWWW Foundation INC dba QuadW · 2025–2026 · via Children's Oncology Group
COG 264538
Sub-PI
Work Order to the Master Subcontract Agreement for Industry Funding Sources APEC14B1, AOST2031, AOST2032 (Milestone based)
Children's Oncology Group · 2023–2026 · via Public Health Institute
PHI AR67220
Sub-PI
ST. BALDRICK'S FOUNDATION SUPPLEMENTAL PER-CASE REIMBURSEMENT 2023
St. Baldrick's Foundation · 2023–2026 · via Children's Oncology Group
COG 230607-01

Completed grants (3)

Sub-PI
Children's Oncology Group NCI Community Oncology Research Program (NCORP) Research Base Grant
National Cancer Institute · 2021–2025 · via Public Health Institute
7 UG1 CA189955- 08
PI
Project: Every Child
Children's Oncology Group · 2023–2025
COG- EveryChild 230613-01
Sub-PI
Amazon Supplemental Payments 2023
Amazon Web Services, Inc. · 2023–2025 · via Children's Oncology Group
COG- Amazon 230611-01

Clinical research

Active

7 studies

PI
Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)
PHASE3 · Children's Oncology Group · OPEN TO ACCRUAL (as of 2026)
Stage I Mixed Cell Type Kidney Wilms Tumor; Stage II Mixed Cell Type Kidney Wilms Tumor; Stage III Mixed Cell Type Kidney Wilms Tumor; Stage IV Mixed Cell Type Kidney Wilms Tumor
NCT06401330
PI
Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults With Cancer
PHASE3 · Children's Oncology Group · OPEN TO ACCRUAL (as of 2026)
Hematopoietic and Lymphatic System Neoplasm; Malignant Solid Neoplasm
NCT06513962
PI
A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination With Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
PHASE2; PHASE3 · Children's Oncology Group · OPEN TO ACCRUAL (as of 2025)
High Grade Osteosarcoma; Localized Osteosarcoma; Metastatic Osteosarcoma; Secondary Osteosarcoma
NCT05691478
PI
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
PHASE3 · Children's Oncology Group · OPEN TO ACCRUAL (as of 2025)
Acute Myeloid Leukemia
NCT04293562
PI
Art Therapy in a hematology/oncology/bone marrow transplant clinics for Pediatric, Adolescent, and Young Adult patients: A pilot multi-site mixed methods observational study
Drexel University · OPEN TO ACCRUAL (as of 2023)
PI
Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
PHASE3 · Children's Oncology Group · OPEN TO ACCRUAL (as of 2021)
Germ Cell Tumor
NCT02582697
PI
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
PHASE2 · Children's Oncology Group · OPEN TO ACCRUAL (as of 2021)
Anaplastic Kidney Wilms Tumor; Recurrent Kidney Wilms Tumor; Stage II Kidney Wilms Tumor; Stage III Kidney Wilms Tumor; Stage IV Kidney Wilms Tumor
NCT04322318

Completed & closed trials (8)

PI
Renal Tumors Classification, Biology, and Banking Study
Children's Oncology Group · IRB STUDY CLOSURE (as of 2026)
Adult Cystic Nephroma; Anaplastic Kidney Wilms Tumor; Angiolipoma; Cellular Congenital Mesoblastic Nephroma; Classic Congenital Mesoblastic Nephroma; Clear Cell Sarcoma of the Kidney; Congenital Mesoblastic Nephroma; Cystic Partially Differentiated Kidney Nephroblastoma; Diffuse Hyperplastic Perilobar Nephroblastomatosis; Extrarenal Rhabdoid Tumor; Kidney Medullary Carcinoma; Kidney Neoplasm; Kidney Oncocytoma; Kidney Wilms Tumor; Metanephric Adenofibroma; Metanephric Adenoma; Metanephric Stromal Tumor; Metanephric Tumor; Mixed Congenital Mesoblastic Nephroma; Ossifying Renal Tumor of Infancy; Papillary Renal Cell Carcinoma; Renal Cell Carcinoma; Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions; Rhabdoid Tumor of the Kidney; Wilms Tumor
NCT00898365
PI
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients With High Risk Rhabdomyosarcoma (HR-RMS)
PHASE3 · Children's Oncology Group · IRB STUDY CLOSURE (as of 2026)
Alveolar Rhabdomyosarcoma; Botryoid-Type Embryonal Rhabdomyosarcoma; Embryonal Rhabdomyosarcoma; Metastatic Embryonal Rhabdomyosarcoma; Metastatic Rhabdomyosarcoma; Solid Alveolar Rhabdomyosarcoma; Spindle Cell Rhabdomyosarcoma; Spindle Cell/Sclerosing Rhabdomyosarcoma
NCT04994132
PI
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
PHASE3 · Children's Oncology Group · IRB STUDY CLOSURE (as of 2025)
Childhood Hepatocellular Carcinoma; Childhood Malignant Liver Neoplasm; Fibrolamellar Carcinoma; Hepatoblastoma; Hepatocellular Malignant Neoplasm, Not Otherwise Specified
NCT03533582
PI
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
PHASE2 · Children's Oncology Group · IRB STUDY CLOSURE (as of 2025)
Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
NCT03817398
PI
Lymphocyte Count, Lymphocyte-to-Monocyte Ratio, and Lymphocyte-to-Neutrophil Ratio Pre and Post-Chemotherapy as Prognostic Factors in Pediatric Solid Tumors.
Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2024)
PI
UA COVID-19 National Registry: National Registry of Pediatric Cancer Patients Diagnosed with COVID-19
University of Alabama · IRB STUDY CLOSURE (as of 2024)
PI
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
PHASE3 · Children's Oncology Group · CLOSED TO ACCRUAL (as of 2024)
B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Down Syndrome
NCT03914625
PI
MCC 20320: Blood Based Biomarkers for Minimal Residual Disease Detection in Pediatric Sarcomas
H. Lee Moffitt Cancer Center & Research Institute · IRB STUDY CLOSURE (as of 2023)

External relationships

Ownership

Pfizer, Inc.

Professional Services

BMS

Other

Caris Life Sciences